PhD Students - Pharmaceutical Sciences, University of Basel’s Post

It is our great pleasure to share Anna Bollinger’s latest publication “Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report.” Understanding a patient’s family health history (FHH) is crucial in clinical practice, however, it is often overlooked as it relies on subjective, self-reported information. Could pharmacogenetic (PGx) testing bridge this gap and validate self-reported drug-related problems (DRP) in FHH? This case study involving the genotyping of 10 family members of three generations demonstrates its potential: A nine-year-old girl underwent a preemptive PGx panel test before surgery due to her grandmothers’ self-reported DRPs in a perioperative context. PGx testing identified the girl as a CYP2B6 intermediate metabolizer with reduced enzyme activity and a CYP2D6 poor metabolizer with no enzyme activity, from which therapeutic recommendations for analgesia and anesthesia were deduced. However, the genotype-predicted phenotypes could not be traced back to the grandmothers. This case study illustrates how PGx testing can validate self-reported FHH. Additionally, the preemptive PGx testing results were used to inform perioperative treatment decisions by the anesthesiologist. Curious to read more? 🧐 Follow the link: https://lnkd.in/ezMupB6c #publication #PGx #FHH #DRP

Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report - BMC Anesthesiology

Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report - BMC Anesthesiology

bmcanesthesiol.biomedcentral.com

To view or add a comment, sign in

Explore topics